top of page

The largest cannabis study ever conducted found no evidence it helps anxiety, depression, or PTSD and warned it may be making all three worse

Writer: Breathe Free USA
Breathe Free USA
5 days ago
2 min read

A new study "The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis" was published in The Lancet Psychiatry in March 2026. It reviewed 54 randomized controlled trials that took place over 45 years. In an article reviewing this study, Darlene Alexander notes, "What it found for anxiety, depression, and PTSD was not weak evidence. It was an absence of evidence. The clinical trials conducted over four and a half decades, using the full range of cannabinoid preparations available, across diverse patient populations and study designs, did not produce a reliable signal of therapeutic benefit for the three conditions that now justify the majority of prescriptions."


Anxiety, depression, and PTSD drive the majority of medical cannabis prescriptions across North America, Australia, and Europe.


The study itself states, "Meta-analysis found no benefit of cannabinoids for opioid use disorder, tobacco use disorder, cocaine use disorder, bipolar disorder, anxiety, ADHD, psychotic disorders, PTSD, OCD, or anorexia nervosa.” Furthermore, “There was some evidence that cannabinoids can reduce symptoms of cannabis use disorder, insomnia, tic or Tourette’s syndrome, and autism spectrum disorder, but the quality of this evidence was generally low.”


Regarding the quality of this study, Alexender notes that "the systematic review and meta-analysis methodology, which pools the results of multiple randomized controlled trials to identify patterns across a larger combined dataset than any individual study can provide, represents the highest level of evidence available in clinical medicine. A single clinical trial can be affected by sample size, population selection, dosing protocols, and statistical chance. A meta-analysis of 54 randomized controlled trials across 45 years is not vulnerable to those individual limitations in the same way."


Alexander discusses the gap between perceived effectiveness of cannabis to treat certain conditions versus the actual evidence:


"Cannabis produces immediate pharmacological effects that many people describe as calming, distracting, or mood-lifting. These short-term effects are real. What randomized controlled trials measure is whether those effects translate into clinically meaningful, sustained improvements in the underlying condition over time, compared to a placebo control that accounts for the significant therapeutic effect of believing you have received an active treatment.


"The anxiety and depression that patients report managing with cannabis tends to return between uses. The studies that have tracked symptom trajectories over time have consistently failed to show that cannabinoid treatment produces the durable reduction in disorder severity that defines a clinically effective intervention. The experience of relief is genuine. The relief is not treating the disorder in the way that clinical effectiveness requires it to be treated."


Article reviewing study:

Author: Darlene M. Alexander

Published in thesciverse


Full Study:

Breathe logo 3 tp.png

Breathe Free USA is a community organization that educates about the harms of cannabis legalization and normalization to public health & safety.

Sign Up For Our Mailing List

 

Receive notifications when new articles are posted and information on how to take action with us.

Thanks for submitting!

© 2021 by Breathe Free USA 

bottom of page